Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $2.62 USD
Change Today -0.11 / -4.03%
Volume 88.3K
GALT On Other Exchanges
Symbol
Exchange
NASDAQ CM
Frankfurt
NASDAQ CM
As of 8:10 PM 07/1/15 All times are local (Market data is delayed by at least 15 minutes).

galectin therapeutics inc (GALT) Key Developments

Galectin Therapeutics, Inc. Initiates Enrollment for GR-MD-02 Phase 2 Clinical Trial in Nash with Cirrhosis

Galectin Therapeutics, Inc. announced the screening of the first five patients in its Phase 2 clinical trial with GR-MD-02 in nonalcoholic steatohepatitis (NASH) with cirrhosis. This study, the NASH-CX trial, is a multicenter, randomized, placebo-controlled, double-blind, parallel-group Phase 2 trial to evaluate the safety and efficacy of GR-MD-02 for the treatment of liver fibrosis and resultant portal hypertension in patients with NASH cirrhosis.

Galectin Therapeutics, Inc.(NasdaqCM:GALT) dropped from Russell 2000 Index

Galectin Therapeutics, Inc. will be removed from Russell 2000 Index

Galectin Therapeutics, Inc.(NasdaqCM:GALT) dropped from Russell 3000 Index

Galectin Therapeutics, Inc. will be removed from the Russell 3000 Index.

Galectin Therapeutics, Inc. Presents at Impact Investor Conference, Jun-19-2015

Galectin Therapeutics, Inc. Presents at Impact Investor Conference, Jun-19-2015 . Venue: Minneapolis Club, 729 2nd Ave S, Minneapolis, MN 55402, United States.

Galectin Therapeutics Names Dr. Marc Rubin as Lead Independent Director

Galectin Therapeutics Inc. reported that Marc Rubin, M.D. has been elected by the independent members of the board of directors as the lead independent director. Dr. Rubin has been a member of the Galectin board of directors since 2011 and currently serves on its compensation committee. He is a member of the board of directors of Curis Inc. He also serves as a board member in a number of privately held pharmaceutical companies and non-profit organizations.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
GALT:US $2.62 USD -0.11

GALT Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for GALT.
View Industry Companies
 

Industry Analysis

GALT

Industry Average

Valuation GALT Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 3.0x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact GALECTIN THERAPEUTICS INC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.